PDSB - PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade)
2024-04-29 10:00:00 ET
Summary
- PDS Biotechnology is shifting its focus to a triplet therapy for HPV-positive cancers instead of pursuing approval for PDS0101 alone.
- The company's pivot raises concerns about potential delays and the need for additional funding.
- PDSB has enough cash to fund operations until Q4 2024, but raising funds is a top priority.
Topline Summary
PDS Biotechnology ( PDSB ) is an immunotherapy-focused biotech that I've offered some positive thoughts on in a previous article . Back in January, I highlighted some promising, though early, clinical trial data that signals forward momentum in the space of virus-driven cancer. However, cash was a concern for the company, with around 1 year of runway as they head into more and more advanced (and expensive clinical development)....
PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade)